Diligence memo · auto-generated · as of July 2, 2026
Radiance Therapeutics, Inc.
Radiance Therapeutics, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Radiance Therapeutics, Inc. operates in Pharma, based in TUCSON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Radiance Therapeutics, Inc. has raised $19M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $9.0M on 2020-12-10.
Most recent recorded round closed around 2020-12-10.
Valuation (modeled)modeled
Provath models Radiance Therapeutics, Inc. at approximately $228M (range $10M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.19× the median modeled value of Series A Pharma companies in 2019–2021 (24 peers) — value vs value, same stage and era. Within the normal band (119% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 5.6 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round was 4.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 75% of Pharma peers (310 compared).
Modeled value ranks above 78% of those peers.
Closest niche peers: Comet Therapeutics, Inc., RadImmune Therapeutics, Inc., Nanoscope Therapeutics, Inc., ZebiAI Therapeutics, Inc., Blue Note Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.